Marketing-authorisation holder · United States
Novo Nordisk Inc.
66 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
66 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 66
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALHEMO150mg/1.5ml(100mg/ml) | 300mg/3ml(100mg/ml) | 60mg/1.5ml(40mg/ml) · Injectable | Concizumab | United States | Marketed | 2024 |
| ALHEMO150mg/1.5ml (100mg/ml) | 300mg/3ml (100mg/ml) | 60mg/1.5ml (40mg/ml) · Solution | Concizumab | United States | Marketed | 2025 |
| Awiqli700units/ml · Injection | Insulin icodec | United States | Marketed | 2026 |
| Awiqli1,050units/1.5ml (700units/ml) · Injection | Insulin icodec | United States | Marketed | 2026 |
| AWIQLI FLEXTOUCHInjection | Insulin icodec | United States | Marketed | 2026 |
| Esperoct1500iu · For Injection | Antihemophilic factor glycopegylated | United States | Marketed | 2019 |
| Esperoct5000iu · For Injection | Antihemophilic factor glycopegylated | United States | Marketed | 2024 |
| Esperoct2000iu · For Injection | Antihemophilic factor glycopegylated | United States | Marketed | 2019 |
| Esperoct1000iu · For Injection | Antihemophilic factor glycopegylated | United States | Marketed | 2019 |
| Esperoct4000iu · For Injection | Antihemophilic factor glycopegylated | United States | Marketed | 2024 |
| Esperoct3000iu · For Injection | Antihemophilic factor glycopegylated | United States | Marketed | 2019 |
| Esperoct500iu · For Injection | Antihemophilic factor glycopegylated | United States | Marketed | 2019 |
| Fiasp160units/1.6ml (100units/ml) · Injection | Insulin aspart | United States | Marketed | 2023 |
| GLUCAGEN1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Powder | Glucagon | United States | Not marketed | 1998 |
| GLUCAGEN1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Powder | Glucagon | United States | Not marketed | 1998 |
| INNOFEM0.5mg | 1mg | 2mg · Tablet | Estradiol | United States | Not marketed | 1999 |
| LEVEMIR1000 units/10ml (100 units/ml) · Injectable | Insulin detemir recombinant | United States | Marketed | 2005 |
| LEVEMIR100 units/ml · Injectable | Insulin detemir | United States | Marketed | 2005 |
| LEVEMIR FLEXPEN300 units/3ml (100 units/ml) · Injectable | Insulin detemir recombinant | United States | Not marketed | 2005 |
| LEVEMIR FLEXTOUCH300 units/3ml (100 units/ml) · Injectable | Insulin detemir recombinant | United States | Marketed | 2005 |
| LEVEMIR INNOLET300 units/3ml (100 units/ml) · Injectable | Insulin detemir recombinant | United States | Not marketed | 2005 |
| LEVEMIR PENFILL300 units/3ml (100 units/ml) · Injectable | Insulin detemir recombinant | United States | Not marketed | 2005 |
| NORDITROPIN10mg/1.5ml | 15mg/1.5ml | 5mg/1.5ml · Injectable | Somatropin | United States | Not marketed | 2000 |
| NORDITROPIN FLEXPRO10mg/1.5ml | 15mg/1.5ml | 30mg/3ml | 5mg/1.5ml · Injectable | Somatropin | United States | Marketed | 2000 |
| NORDITROPIN NORDIFLEX10mg/1.5ml | 15mg/1.5ml | 30mg/3ml | 5mg/1.5ml · Injectable | Somatropin | United States | Not marketed | 2000 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 66 | 65 | 1 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.